Navigation Links
Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Date:5/7/2012

acted as the exclusive advisor to Coherus BioSciences in this licensing partnership with Daiichi Sankyo.

About Coherus BioSciences

Coherus BioSciences is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area with an entirely new model for developing safe, high-quality biosimilar therapeutics.  Founded in 2010, Coherus already has formed global partnerships with top tier pharma and filled the pipeline with five product candidates focused on treating oncology and inflammatory diseases.  Led by a group of early biotech pioneers, Coherus has reinvented the entire business of developing biologic medicines, from concept to commercialization, so that more patients around the world can have greater access to quality therapeutics. For additional information, please visit www.coherus.com.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Contact: Maureen Lopez
Coherus BioSciences
Phone Number 1-800-794-5434

Media contact for Daiichi Sankyo Co. Ltd.: +81-3-6225-1126


'/>"/>
SOURCE Coherus BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Spherix Incorporated (SPEX) -- an intellectual property development company committed ... that the United States Patent & Trademark Office (USPTO) issued ... September that is part of a standard essential family of ... , Application number: US 13/728,867 , Publication date: ... The listed inventors of the new patent, ...
(Date:9/20/2014)... HealthTronics, Inc. , a leading ... and services, has signed a distribution agreement through ... for its high precision laser technology. ... mobile, surgical technology—offering more choices for healthcare providers ... will make available Clinicon’s FDA-cleared SureLase™ CO2 Laser ...
(Date:9/19/2014)... than electricity, to move data would consume much ... growing concern as chips, transistor counts rise. , ... light emitters, modulators, and detectors emitters ... source for optical chips is molybdenum disulfide (MoS2), ... a single, atom-thick layer. Other experimental on-chip light ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
Breaking Biology Technology:Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2
... could prove efficacious for both prophylactic and ... Corporation (NYSE AMEX: CVM ) ... that vaccines utilizing its proprietary L.E.A.P.S.(TM) (Ligand ... potentially induce protection against illnesses such as ...
... AKIVA, Israel, April 28 ITGI Medical, Ltd.,(TASE: ... and,marketing of heterologous tissue covered stents, announced that ... HUD (Humanitarian Use Device),designation to Over and Under(R) ... and dissections of native coronary arteries and,Saphenous Vein ...
... Inc. (NYSE Amex: PIP ), a biodefense ... announced today that results from a second Phase II ... Annual Conference on Vaccine Research, being held in Baltimore, ... the National Foundation of Infectious Diseases.David P. Wright, President ...
Cached Biology Technology:CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 2PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 4PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 5PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 6PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 7
(Date:9/19/2014)... of Oklahoma biology professor will study the unique bioelectric ... could eventually benefit people,s health. The OU researcher ... energy required to produce the signals used to map ... signals at a rate of 500-600 discharges a second ... the electric fish are extreme, but necessary for survival. ...
(Date:9/19/2014)... , Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: ... company focused on the growing m-commerce market, updates the "Wocket in ... in the lightweight and light middleweight weight classes, Vinny Pazienza ... was announced that Game of Thrones actor Ciaran ... with Children star Katey Sagal have been cast ...
(Date:9/18/2014)... sleep-promoting circuit located deep in the primitive brainstem has ... researchers at Harvard School of Medicine and the University ... is only the second "sleep node" identified in the ... and sufficient to produce deep sleep. , Published online ... demonstrates that fully half of all of the brain,s ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... , March 27, 2013  Definiens, the global leader of ... today announced it has appointed an Advisory Board comprising ... part of its market expansion strategy, Definiens established the ... opportunities in tissue diagnostics and clinical digital pathology. Members ...
... to prevent people with HIV from also becoming infected with ... State University. Behaviors that put people at higher risk ... getting blood transfusions, for instance also raise their risk ... liver and, if untreated, can be deadly. The study, ...
... (March. 27, 2013) A team of ... improve the neurobehavioral function of six week-old ... (ASCs) to treat hypoxic-ischemic brain injury, and found ... animals through exercise-induced fibroblast growth factor 2 (FGF2), ...
Cached Biology News:Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board 2Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board 3HIV sufferers need hepatitis safeguards 2Environmental enrichment important factor impacting cell transplantation and brain repair 2Environmental enrichment important factor impacting cell transplantation and brain repair 3
... Drosophila S2 cells are used for heterologous ... System (DES). The S2 cell line was ... (20-24 hours old) Drosophila melanogaster embryos ... at room temperature without CO2 and is easily ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. Feature: tissue-culture treated yes ... cm 2 D H 60 ...
... Nop1p/Fibrillarin was originally identified ... yeast, Saccharomyces cerevisiae (accession P15646). The ... viability and is localized in the ... is fibrillarin (accession P22087) a component ...
Biology Products: